HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Test for Immortality in the Reference Lab

Executive Summary

Early-stage biotechnology is hardly the most popular investment in health care these days, but Geron is doing just fine despite the fact that its clinical target, telomerase, still awaits definitive proof of value and that it has yet to clone the entire molecule.

You may also be interested in...



CMS Expands Reimbursement Time For Comprehensive Care For Joint-Replacement Model

Due to the COVID-19 crisis, the US Medicare agency is extending the length of time it will support its Comprehensive Care for Joint Replacement bundled payment reimbursement model.

US FDA Facility Compliance Actions Could Speed Up Despite Inspections Freeze, Attorney Says

With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.

Royal Philips’ $646M Deal: US Govt Uses Defense Production Act To Order 45,500 Ventilators

Philips will make 43,000 medical ventilators by the end of 2020 for use in the US and manufacture 2,500 more for the Strategic National Stockpile in a contract worth more than half a billion dollars.

Topics

UsernamePublicRestriction

Register

IV000365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel